Sutro Biopharma Files 8-K

TL;DR

Sutro Biopharma filed an 8-K, but it's light on details for now.

AI Summary

On December 10, 2024, Sutro Biopharma, Inc. filed an 8-K report. The filing does not contain specific details about events, financial figures, or material changes, indicating it may be a routine or placeholder filing.

Why It Matters

This filing indicates Sutro Biopharma has submitted a report to the SEC, but without further details, its immediate impact on investors or operations is unclear.

Risk Assessment

Risk Level: low — The filing is a standard 8-K without disclosed material events, suggesting no immediate new risks.

Key Players & Entities

• SUTRO BIOPHARMA, INC. (company) — Registrant
• December 10, 2024 (date) — Date of earliest event reported
• 111 Oyster Point Blvd. South San Francisco , California , 94080 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common stock, $0.001 par value STRO The NASDAQ Stock Mar

Filing Documents

• stro-20241210.htm (8-K) — 45KB
• 0000950170-24-134765.txt ( ) — 155KB
• stro-20241210.xsd (EX-101.SCH) — 25KB
• stro-20241210_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On December 10, 2024, Sutro Biopharma, Inc. (the "Company") announced the selected dose from the dose-optimization portion (Part 1) of REFRME-O1, the registration-directed trial of luveltamab tazevibulin ("luvelta"), a novel folate receptor- (FolR) targeting antibody drug conjugate ("ADC"), in platinum-resistant ovarian cancer ("PROC"). REFRME-O1 (Part 1): REFRME-O1 (Part 1) evaluated luvelta in patients with PROC with low, medium, and high FR expression levels. This includes patients with 25% Tumor Proportion Score (TPS), defined as at least 25% of tumor cells expressing FR, at any staining intensity. In the dose-optimization (Part 1), patients were randomized 1:1 to a 5.2 mg/kg with prophylactic pegfilgrastim (G-CSF) for 2 cycles followed by 4.3 mg/kg for subsequent cycles (5.2 mg/kg group), or a 4.3 mg/kg dose of luvelta for all cycles (4.3 mg/kg group). Topline Results from evaluable patients (5.2 mg/kg group; N = 25): Achieved an objective response rate of 32%, which includes one partial response that confirmed post data extraction (as of August 16, 2024) Disease control rate of 96% Approximately half of the patients treated were ineligible for an approved FR-targeting ADC 88% of patients received prior bevacizumab Grade 3 or higher neutropenia occurred in 32% of patients, no febrile neutropenia REFRME-O1 (Part 2) Registrational Trial: REFRME-O1 (Part 2) is an ongoing global registrational trial for patients with PROC, evaluating a 5.2 mg/kg dose with prophylactic pegfilgrastim (G-CSF) for the first two cycles followed by a 4.3 mg/kg dose for subsequent cycles. Part 2 will enroll approximately 500 patients, randomized 1:1 to luvelta or investigators' choice of chemotherapy. This Current Report on Form 8-K contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sutro Biopharma, Inc. Date: December 10, 2024 By: /s/ Edward Albini Edward Albini Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR